1. Clinical Trial — Glycemic Control in Type 2 Diabetes
   A randomized clinical study found that chromium picolinate supplementation significantly reduced fasting and postprandial glucose and improved HbA1c in patients with poorly controlled type 2 diabetes over four months, suggesting benefits in glycemic control.

2. Review — Clinical Studies on Diabetes
   A review of 15 clinical studies (including randomized controlled trials) reported that the majority of chromium picolinate interventions improved at least one parameter of glycemic control—such as blood glucose, insulin levels, or lipid profiles—suggesting potential benefits in diabetes management.

3. Health Professional Fact Sheet (NIH Office of Dietary Supplements)
   The NIH fact sheet summarizes intervention trials where supplemental chromium (mostly as picolinate) lowered fasting glucose and insulin concentrations in some studies, particularly at higher doses (200–1000 mcg/day), although results varied by outcome and population.

4. Scientific Review — Insulin Resistance and Chromium
   A scientific review reported that chromium plays a role in enhancing insulin activity and carbohydrate metabolism, and that chromium picolinate supplementation (200–1000 mcg/day) has shown effects on insulin sensitivity in several studies.

5. Systematic Review — Controversial Evidence
   Some recent systematic reviews highlight that evidence on chromium supplementation and glucose/lipid control is mixed and not uniformly conclusive, underscoring the need for further high-quality research.

6. Study in Metabolic Syndrome
   A placebo-controlled trial in obese adults with metabolic syndrome showed no significant improvement in insulin sensitivity or other metabolic features with chromium picolinate at higher doses, illustrating inconsistent effects across different populations.

Key Takeaways for Medical Description

• Mechanism: Chromium is a trace element involved in enhancing insulin signaling and carbohydrate metabolism.
• Clinical Findings: Evidence from multiple randomized controlled trials suggests potential improvements in glycemic control parameters (e.g., fasting glucose, HbA1c, insulin levels) in some individuals, especially in type 2 diabetes.
• Variability: Results vary across studies and populations; benefits are not universally observed, and some trials report no significant effects.
• Dosing in Research: Clinical trials have tested chromium picolinate in ranges from ~200 mcg/day up to 1000 mcg/day, with mixed outcomes. 

Write a review